We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+17.24%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$345M
AUM Growth
–
Cap. Flow
+$314M
Cap. Flow
% of AUM
91.14%
Top 10 Holdings %
Top 10 Hldgs %
62.86%
Holding
37
New
37
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$33M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$25.9M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$21.6M |
| 4 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$20.3M |
| 5 |
CELG
Celgene Corp
CELG
|
+$19M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
| $34.9M | 10.13% |
+1,093,800
| New | +$33M |
|
|
CBST
2
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $27.5M | 7.99% |
+400,000
| New | +$25.9M |
|
|
KERX
3
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $22M | 6.39% |
+1,700,000
| New | +$20.3M |
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $21.5M | 6.23% |
+2,850,000
| New | +$21.6M |
|
5
Puma Biotechnology
PBYI
$402M
| $20.7M | 6.01% |
+200,000
| New | +$11.7M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $20.3M | 5.88% |
+240,000
| New | +$19M |
|
7
Acadia Pharmaceuticals
ACAD
$4.55B
| $20M | 5.8% |
+800,000
| New | +$18.9M |
|
|
IDIX
8
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $17.5M | 5.08% |
+2,925,000
| New | +$13.5M |
|
9
Geron
GERN
$860M
| $16.1M | 4.67% |
+3,594,191
| New | +$15.4M |
|
10
Alnylam Pharmaceuticals
ALNY
$27.4B
| $16.1M | 4.67% |
+250,000
| New | +$14.9M |
|
11
Bristol-Myers Squibb
BMY
$132B
| $14.4M | 4.16% |
+270,000
| New | +$13.8M |
|
12
Arrowhead Research
ARWR
$12.3B
| $10.8M | 3.13% |
+995,500
| New | +$7.96M |
|
13
DexCom
DXCM
$28.8B
| $10.6M | 3.08% |
+1,200,000
| New | +$9.5M |
|
|
RCPT
14
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $10.1M | 2.94% |
+350,000
| New | +$9.38M |
|
|
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
| $8.77M | 2.54% |
+1,750,000
| New | +$9.53M |
|
16
Talphera
TLPH
$70.1M
| $8.48M | 2.46% |
+37,500
| New | +$6.52M |
|
|
TSRO
17
DELISTED
TESARO, Inc.
TSRO
| $8.47M | 2.46% |
+300,000
| New | +$11.1M |
|
|
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
| $7.19M | 2.09% |
+119,300
| New | +$6.49M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.7B
| $7.04M | 2.04% |
+100,000
| New | +$6.79M |
|
|
AMAG
20
DELISTED
AMAG Pharmaceuticals
AMAG
| $6.07M | 1.76% |
+250,000
| New | +$5.88M |
|
21
Insulet
PODD
$11.5B
| $5.57M | 1.62% |
+150,000
| New | +$5.54M |
|
22
Novavax
NVAX
$1.22B
| $5.12M | 1.49% |
+50,000
| New | +$3.53M |
|
23
Pacira BioSciences
PCRX
$1.06B
| $2.88M | 0.83% |
+50,000
| New | +$2.63M |
|
|
SGMO
24
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $2.31M | 0.67% |
+166,200
| New | +$1.91M |
|
25
Karyopharm Therapeutics
KPTI
$159M
| $2.29M | 0.67% |
+6,667
| New | +$1.84M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Cormorant Asset Management, which disclosed 37 positions worth $345M. Its ten largest holdings account for 63% of the portfolio.
Its largest position is MEDIVATION, INC.: 1,093,800 shares worth $34.9M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets.
- Cormorant Asset Management's largest Q4 2013 buy was MEDIVATION, INC.: 1,093,800 shares worth $34.9M.
- Cormorant Asset Management's ten largest holdings make up 63% of its $345M portfolio in Q4 2013.
- Cormorant Asset Management disclosed 37 positions in Q4 2013, its first 13F filing on record.
Based on Cormorant Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.